Taken together, blocking production of HA, one of the main ligands for CD44, inhibits growth of bladder cancer cells in vitro and in mouse xenograft models, supporting the notion that CD44 functioning as a receptor is a driver of bladder cancer growth, progression, and recurrence. This evidence concerns the gene CD44 and urinary bladder cancer.